Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy.
Rossella RubinoAndrea MariniGiandomenico RovielloElena Margherita PresottoIsacco DesideriIsabella CiardettiMarco BrugiaNicola PimpinelliLorenzo AntonuzzoEnrico MiniLorenzo LiviMario MaggiAlessandro PeriPublished in: Endocrine (2021)
Thyroid alterations are frequently observed in cancer patients treated with anti PD-1 drugs, particularly in women and in the presence of a previous endocrinopathy. We suggest that regular thyroid assessment should be performed in these patients, especially in the first months of therapy. Finally, the onset of side effects, related to anti PD-1 agents, appears to be associated with a better outcome.